Journal of Neural Transmission 2010-06-01

Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.

B Szende, G Barna, Kálmán Magyar

Index: J. Neural Transm. Gen. Sect. 117(6) , 695-8, (2010)

Full Text: HTML

Abstract

Postulated cytoprotective action of (-)-deprenyl (D), (-)-desmethyl-deprenyl (DD) and (-)-deprenyl-N-oxide (DNO) on L-buthionine-(S,R)-sulfoximine (BSO) toxicity was investigated using in vitro cultures of serum-deprived A-2058 melanoma cells. BSO (10 microM/l) decreased viable cell number and mitotic rate, while increased the apoptotic index. D and both of its metabolites, given together with BSO in the concentration of 50 microM/l, mitigated cell loss and decreased the apoptotic ratio. DD was the most effective compound in decreasing apoptotic activity, while DNO stabilized the cell number on control level and increasing the ratio of mitotic cells above the only serum-deprived control. Surveillance on mitochondrial membrane stability and antioxidant properties may play an important role in these processes.


Related Compounds

Related Articles:

Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry.

2006-12-05

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 844(2) , 283-91, (2006)]

Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.

2002-04-30

[Mech. Ageing Dev. 123(8) , 1065-79, (2002)]

Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.

2007-01-01

[J. Neural Transm. Suppl. (72) , 165-73, (2007)]

P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.

2007-04-01

[Drug Metab. Pharmacokinet. 22(2) , 78-87, (2007)]

Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.

2000-01-01

[Clin. Neuropharmacol. 23(1) , 22-7, (2000)]

More Articles...